Remo Guerrini

List of Publications by Year
in descending order

259 papers	10,013 citations	36303 51 h-index	54911 84 g-index
261 all docs	261 docs citations	261 times ranked	6662 citing authors

#	Article	IF	Citations
1	Solution structure of the Alzheimer amyloid Î²â€peptide (1â€“42) in an apolar microenvironment. FEBS Journal, 2002, 269, 5642-5648.	0.2	577
2	Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature, 2012, 485, 395-399.	27.8	430
3	Pharmacology of nociceptin and its receptor: a novel therapeutic target. British Journal of Pharmacology, 2000, 129, 1261-1283.	5.4	395
4	The Î±-to-Î² Conformational Transition of Alzheimer's AÎ²-(1-42) Peptide in Aqueous Media is Reversible: A Step by Step Conformational Analysis Suggests the Location of Î² Conformation Seeding. ChemBioChem, 2006, 7, 257-267.	2.6	375
5	Address and Message Sequences for the Nociceptin Receptor:â€‰ A Structureâ"Activity Study of Nociceptin-(1â"13)-peptide amide. Journal of Medicinal Chemistry, 1997, 40, 1789-1793.	6.4	224
6	A new selective antagonist of the nociceptin receptor. British Journal of Pharmacology, 1998, 123, 163-165.	5.4	221
7	Characterization of [Nphe1]nociceptin(1-13)NH2 , a new selective nociceptin receptor antagonist. British Journal of Pharmacology, 2000, 129, 1183-1193.	5.4	178
8	[Nphe¹,Arg¹⁴,Lys¹⁵]Nociceptinâ€NH₂, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. British Journal of Pharmacology, 2002, 136, 303-311.	5.4	158
9	The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. European Journal of Pharmacology, 1996, 311, R3-R5.	3.5	122
10	Solution Structure of Amyloid Î²-Peptide (25â"35) in Different Media. Journal of Medicinal Chemistry, 2004, 47, 4231-4238.	6.4	117
11	Blockade of Nociceptin/Orphanin FQ Transmission Attenuates Symptoms and Neurodegeneration Associated with Parkinson's Disease. Journal of Neuroscience, 2005, 25, 9591-9601.	3.6	116
12	Î´ Opioidmimetic Antagonists: Prototypes for Designing a New Generation of Ultraselective Opioid Peptides. Molecular Medicine, 1995, 1, 678-689.	4.4	116
13	Blockade of Nociceptin/Orphanin FQ Receptor Signaling in Rat Substantia Nigra Pars Reticulata Stimulates Nigrostriatal Dopaminergic Transmission and Motor Behavior. Journal of Neuroscience, 2004, 24, 6659-6666.	3.6	109
14	Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. Naunyn-Schmiedeberg's Archives of Pharmacology, 1999, 359, 160-167.	3.0	104
15	Nociceptin/orphanin FQ receptor ligands. Peptides, 2000, 21, 935-947.	2.4	96
16	Evaluation of the Dmtâ"Tic Pharmacophore:Â Conversion of a Potent Î´-Opioid Receptor Antagonist into a Potent Î´ Agonist and Ligands with Mixed Properties. Journal of Medicinal Chemistry, 2002, 45, 713-720.	6.4	93
17	Structure-Activity Studies on Neuropeptide S. Journal of Biological Chemistry, 2006, 281, 20809-20816.	3.4	89
18	Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Medicinal Research Reviews, 2010, 30, 751-777.	10.5	89

#	Article	IF	Citations
19	UFPâ€101, a Peptide Antagonist Selective for the Nociceptin/Orphanin FQ Receptor. CNS Neuroscience & Therapeutics, 2005, 11, 97-112.	4.0	88
20	Anxiolytic-like effect of neuropeptide S in the rat defensive burying. Peptides, 2008, 29, 2286-2291.	2.4	88
21	Evolution of the Dmt-Tic Pharmacophore:Â N-Terminal Methylated Derivatives with Extraordinary Î´ Opioid Antagonist Activity. Journal of Medicinal Chemistry, 1997, 40, 3100-3108.	6.4	85
22	Potent Î´-Opioid Receptor Agonists Containing the Dmtâ”Tic Pharmacophore. Journal of Medicinal Chemistry, 2002, 45, 5556-5563.	6.4	85
23	Structureâ”Activity Study of the Nociceptin(1â”13)-NH2N-Terminal Tetrapeptide and Discovery of a Nociceptin Receptor Antagonist. Journal of Medicinal Chemistry, 1998, 41, 3360-3366.	6.4	81
24	Proteinâ€“protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E542-9.	7.1	77
25	Comparison of the effects of [Phe1 Î¨(CH2 -NH)Gly2]Nociceptin (1-13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors. British Journal of Pharmacology, 1999, 127, 123-130.	5.4	76
26	Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides, 2008, 29, 93-103.	2.4	75
27	Nociceptin/orphanin FQ exacerbates excitotoxic white-matter lesions in the murine neonatal brain. Journal of Clinical Investigation, 2001, 107, 457-466.	8.2	73
28	In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides, 2007, 28, 1240-1251.	2.4	72
29	Further Studies on the Dmt-Tic Pharmacophore:Â Hydrophobic Substituents at the C-Terminus Endow Î´ Antagonists To Manifest Î¼ Agonism or Î¼ Antagonism. Journal of Medicinal Chemistry, 1999, 42, 5010-5019.	6.4	71
30	Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain, 2010, 148, 107-113.	4.2	70
31	Cardiovascular Effects of Nociceptin in Unanesthetized Mice. Hypertension, 1999, 33, 914-919.	2.7	68
32	Further Studies on Nociceptin-Related Peptides:Â Discovery of a New Chemical Template with Antagonist Activity on the Nociceptin Receptor. Journal of Medicinal Chemistry, 2000, 43, 2805-2813.	6.4	68
33	Chronic treatment with the selective NOP receptor antagonist [Nphe1,Arg14,Lys15]N/OFQ-NH2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats. Psychopharmacology, 2009, 207, 173-189.	3.1	66
34	[Nphe1]nociceptin-(1â€“13)-NH2 antagonizes nociceptin effects in the mouse colon. European Journal of Pharmacology, 1999, 385, R3-R5.	3.5	64
35	The Importance of Ligand-Receptor Conformational Pairs in Stabilization: Spotlight on the N/OFQ G Protein-Coupled Receptor. Structure, 2015, 23, 2291-2299.	3.3	64
36	Copper Binding to the Neurotoxic Peptide PrP106-126: Thermodynamic and Structural Studies. ChemBioChem, 2004, 5, 349-359.	2.6	63

#	Article	IF	Citations
37	Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: Pharmacological and genetic evidences. Pain, 2006, 124, 100-108.	4.2	60
38	Structural and Dynamic Characterization of Copper(II) Binding of the Human Prion Protein Outside the Octarepeat Region. Chemistry - A European Journal, 2007, 13, 1991-2001.	3.3	60
39	Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test. British Journal of Pharmacology, 2002, 136, 764-772.	5.4	59
40	Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Gî±qi5. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 599-607.	3.0	59
41	Synthesis and Pharmacological Activity of Deltorphin and Dermorphin-Related Glycopeptides. Journal of Medicinal Chemistry, 1997, 40, 2948-2952.	6.4	58
42	Pharmacological Profile Of Nociceptin/Orphanin Fq Receptors. Clinical and Experimental Pharmacology and Physiology, 2002, 29, 223-228.	1.9	58
43	Immunosensing by a Synthetic Ligand-Gated Ion Channel. Angewandte Chemie - International Edition, 2001, 40, 1740-1743.	13.8	57
44	Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. British Journal of Pharmacology, 2003, 138, 91-98.	5.4	57
45	In Vitro and in Vivo Pharmacological Characterization of the Neuropeptide S Receptor Antagonist [d-Cys(tBu)5]Neuropeptide S. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 549-555.	2.5	55
46	Neuropeptide S: a novel regulator of pain-related amygdala plasticity and behaviors. Journal of Neurophysiology, 2013, 110, 1765-1781.	1.8	55
47	Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 161-165.	3.0	53
48	A new ligand for the urotensin II receptor. British Journal of Pharmacology, 2002, 137, 311-314.	5.4	53
49	Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. European Journal of Pharmacology, 2004, 498, 83-86.	3.5	53
50	Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists. Journal of Medicinal Chemistry, 2009, 52, 524-529.	6.4	53
51	Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. Peptides, 2010, 31, 915-925.	2.4	53
52	[Arg14,Lys15]Nociceptin, a Highly Potent Agonist of the Nociceptin/Orphanin FQ Receptor: in Vitro and in Vivo Studies. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 57-63.	2.5	52
53	Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Cî±,î±-dialkylated amino acids. Bioorganic and Medicinal Chemistry, 2007, 15, 4434-4443.	3.0	51
54	Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist. Pharmacology Research and Perspectives, 2016, 4, e00247.	2.4	51

#	Article	IF	Citations
55	Selective Breeding for High Anxiety Introduces a Synonymous SNP That Increases Neuropeptide S Receptor Activity. Journal of Neuroscience, 2015, 35, 4599-4613.	3.6	50
56	CuII binding sites located at His-96 and His-111 of the human prion protein: thermodynamic and spectroscopic studies on model peptides. Dalton Transactions, 2008, , 5207.	3.3	49
57	Conversion of Enkephalin and Dermorphin into delta-Selective Opioid Antagonists by Single-Residue Substitution. FEBS Journal, 1994, 224, 241-247.	0.2	48
58	Glycation affects fibril formation of Aî² peptides. Journal of Biological Chemistry, 2018, 293, 13100-13111.	3.4	47
59	The nociceptin/orphanin FQ-NOP receptor antagonist effects on an animal model of sepsis. Intensive Care Medicine, 2008, 34, 2284-2290.	8.2	46
60	Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour and biological activity. Biochimica Et Biophysica Acta - General Subjects, 2001, 1526, 199-210.	2.4	45
61	Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study. Urology, 2003, 61, 946-950.	1.0	45
62	Solution Structure of ZASP PDZ Domain. Structure, 2004, 12, 611-622.	3.3	45
63	Pharmacological characterization of the nociceptin receptor which mediates reduction of alcohol drinking in rats. Peptides, 2002, 23, 117-125.	2.4	44
64	RAPID COMMUNICATION: Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. Journal of Neurochemistry, 2004, 91, 1501-1504.	3.9	44
65	Synthesis and antimicrobial activity of dermaseptin S1 analogues. Bioorganic and Medicinal Chemistry, 2008, 16, 8205-8209.	3.0	44
66	URODYNAMIC AND CLINICAL EVIDENCE OF ACUTE INHIBITORY EFFECTS OF INTRAVESICAL NOCICEPTIN/ORPHANIN FQ ON DETRUSOR OVERACTIVITY IN HUMANS: A PILOT STUDY. Journal of Urology, 2001, 166, 2237-2240.	0.4	43
67	Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 551-555.	3.0	43
68	Calmodulin Binding Sites of the Skeletal, Cardiac, and Brain Ryanodine Receptor Ca2+ Channels: Modulation by the Catalytic Subunit of cAMP-Dependent Protein Kinase?. Biochemistry, 1995, 34, 5120-5129.	2.5	41
69	Opioid receptor selectivity alteration by single residue replacement: synthesis and activity profile of [Dmt1]deltorphin B. European Journal of Pharmacology, 1996, 302, 37-42.	3.5	41
70	Opioid Diketopiperazines: Synthesis and Activity of a Prototypic Class of Opioid Antagonists. Biological Chemistry, 1997, 378, 19-29.	2.5	41
71	Structureâ^'Activity Studies of the Phe4Residue of Nociceptin(1â^'13)-NH2:Â Identification of Highly Potent Agonists of the Nociceptin/Orphanin FQ Receptor. Journal of Medicinal Chemistry, 2001, 44, 3956-3964.	6.4	41
72	Design of Î´-opioid peptide antagonists for emerging drug applications. Drug Discovery Today, 1998, 3, 284-294.	6.4	40

#	Article	IF	Citations
73	The nociceptin/orphanin FQ receptor antagonist, [Nphe1]NC(1-13)NH2, potentiates morphine analgesia. NeuroReport, 2000, 11, 2369-2372.	1.2	40
74	Anxiolyticâ€•and panicolyticâ€like effects of Neuropeptide S in the mouse elevated Tâ€•maze. European Journal of Neuroscience, 2012, 36, 3531-3537.	2.6	40
75	Endogenous nociceptin signaling and stress-induced analgesia. NeuroReport, 2001, 12, 3009-3013.	1.2	39
76	Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias. Journal of Neuroscience, 2012, 32, 16106-16119.	3.6	39
77	The paraventricular nucleus of the hypothalamus is a neuroanatomical substrate for the inhibition of palatable food intake by neuropeptide S. European Journal of Neuroscience, 2009, 30, 1594-1602.	2.6	38
78	Structure-activity relationships of nociceptin and related peptides: comparison with dynorphin A. Peptides, 2000, 21, 923-933.	2.4	37
79	Polymorphonuclear neutrophils pulsed with synthetic peptides efficiently activate memory cytotoxic T lymphocytes. Journal of Leukocyte Biology, 1996, 60, 207-213.	3.3	36
80	[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a Highly Potent and Selective Agonist of the Nociceptin/Orphanin FQ Receptor. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 1114-1123.	2.5	36
81	UFP-112 a Potent and Long-Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor. CNS Neuroscience and Therapeutics, 2011, 17, 178-198.	3.9	36
82	Nociceptin Modulates Bronchoconstriction Induced by Sensory Nerve Activation in Mouse Lung. American Journal of Respiratory Cell and Molecular Biology, 2010, 42, 250-254.	2.9	35
83	Structure-activity relationship study on human urotensin II. Journal of Peptide Science, 2005, 11, 85-90.	1.4	34
84	Daily Intravesical Instillation of 1 mg Nociceptin/Orphanin FQ for the Control of Neurogenic Detrusor Overactivity: A Multicenter, Placebo Controlled, Randomized Exploratory Study. Journal of Urology, 2006, 176, 2098-2102.	0.4	34
85	Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. Bioorganic and Medicinal Chemistry, 2006, 14, 692-704.	3.0	34
86	Effects of nociceptin/orphanin FQ receptor ligands on blood pressure, heart rate, and plasma catecholamine concentrations in guinea pigs. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 367, 342-347.	3.0	33
87	Proinflammatory and vasodilator effects of nociceptin/orphanin FQ in the rat mesenteric microcirculation are mediated by histamine. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2977-H2985.	3.2	33
88	Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. European Journal of Pharmacology, 2009, 614, 50-57.	3.5	33
89	Hypothalamic Neuropeptide S receptor blockade decreases discriminative cue-induced reinstatement of cocaine seeking in the rat. Psychopharmacology, 2013, 226, 347-355.	3.1	33
90	Unexpected impact of the number of glutamine residues on metal complex stability. Metallomics, 2013, 5, 214.	2.4	33

#	Article	IF	Citations
91	Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness. Psychopharmacology, 2016, 233, 2525-2532.	3.1	33
92	Structureâ€“activity studies on nociceptin/orphanin FQ: from full agonist, to partial agonist, to pure antagonist. Il Farmaco, 1999, 54, 810-825.	0.9	32
93	Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux. British Journal of Pharmacology, 2005, 144, 813-820.	5.4	32
94	A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ. Bioorganic and Medicinal Chemistry, 2014, 22, 3703-3712.	3.0	32
95	Functional Selectivity of Nociceptin/Orphanin FQ Peptide Receptor Partial Agonists on Cardiovascular and Renal Function. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 643-651.	2.5	31
96	Design and Synthesis of 1-Aminocycloalkane-1-carboxylic Acid-Substituted Deltorphin Analogues:Â Unique Î´ and Î¼ Opioid Activity in Modified Peptides. Journal of Medicinal Chemistry, 1996, 39, 773-780.	6.4	30
97	Identification of a novel 45 kDa protein (JP-45) from rabbit sarcoplasmic-reticulum junctional-face membrane. Biochemical Journal, 2000, 351, 537-543.	3.7	30
98	Studies on the antinociceptive effect of [Nphe1]nociceptin(1â€“13)NH2 in mice. Neuroscience Letters, 2001, 316, 25-28.	2.1	30
99	Gastrointestinal effects of intracerebroventricularly injected nociceptin/orphaninFQ in rats. Peptides, 2004, 25, 1013-1020.	2.4	30
100	In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5 ,D Trp7 ,Dab8]urotensin II(4-11) (UFP-803). British Journal of Pharmacology, 2006, 147, 92-100.	5.4	30
101	Opioid Diketopiperazines: Refinement of the Î´ Opioid Antagonist Pharmacophore. Biological Chemistry, 1997, 378, 107-114.	2.5	29
102	Pharmacological characterisation of [(pX)Phe 4]nociceptin(1-13)amide analogues. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 365, 442-449.	3.0	29
103	UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: Behavioral and electrophysiological studies in mice. Peptides, 2007, 28, 663-669.	2.4	29
104	Blockade of nociceptin/orphanin FQ receptor signaling reverses LPS-induced depressive-like behavior in mice. Peptides, 2015, 72, 95-103.	2.4	29
105	Inverse agonism by Dmtâ€“Tic analogues and HS 378, a naltrindole analogue. European Journal of Pharmacology, 2000, 406, R1-R3.	3.5	28
106	The Coordination of Ni^{II} and Cu^{II} Ions to the Polyhistidyl Motif of Hpn Protein: Is It as Strong as We Think?. Chemistry - A European Journal, 2012, 18, 11088-11099.	3.3	28
107	Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus. Life Sciences, 1999, 64, PL157-PL163.	4.3	27
108	Pharmacological characterisation of [(pX)Phe 4]nociceptin(1-13)NH 2 analogues. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 365, 450-456.	3.0	27

#	Article	IF	Citations
109	Structureâ€“activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4â€²-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide. Bioorganic and Medicinal Chemistry, 2009, 17, 5080-5095.	3.0	27
110	Rational design of dynorphin A analogues with Î´-receptor selectivity and antagonism for Î´- and Îº-receptors. Bioorganic and Medicinal Chemistry, 1998, 6, 57-62.	3.0	26
111	Modeling of overloaded gradient elution of nociceptin/orphanin FQ in reversed-phase liquid chromatography. Journal of Chromatography A, 2005, 1079, 162-172.	3.7	26
112	The unusual metal ion binding ability of histidyl tags and their mutated derivatives. Dalton Transactions, 2016, 45, 5629-5639.	3.3	26
113	Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo). PLoS ONE, 2016, 11, e0156897.	2.5	26
114	Parallel bioassay of 39 tachykinins on 11 smooth muscle preparations. Structure and receptor selectivity/affinity relationship. Peptides, 2000, 21, 1587-1595.	2.4	25
115	N- and C-Terminal Modifications of Nociceptin/Orphanin FQ Generate Highly Potent NOP Receptor Ligands. Journal of Medicinal Chemistry, 2005, 48, 1421-1427.	6.4	25
116	Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 2. Journal of Medicinal Chemistry, 2008, 51, 655-658.	6.4	25
117	Preparation and first biological evaluation of novel Re-188/Tc-99m peptide conjugates with substance-P. Applied Radiation and Isotopes, 2014, 92, 25-31.	1.5	25
118	Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma. British Journal of Pharmacology, 2016, 173, 1286-1301.	5.4	25
119	Effects of [Nphe¹, Arg¹⁴, Lys¹⁵] N/OFQ-NH₂ (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress. Journal of Psychopharmacology, 2017, 31, 691-703.	4.0	25
120	Design and Solution Structure of a Partially Rigid Opioid Antagonist Lacking the Basic Center - Models of Antagonism. FEBS Journal, 1997, 247, 66-73.	0.2	24
121	Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies. European Journal of Immunology, 1999, 29, 2579-2589.	2.9	24
122	Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei. Peptides, 2000, 21, 1663-1671.	2.4	24
123	Copper-ion interaction with the 106â€“113 domain of the prion protein: a solution-equilibria study on model peptides. Dalton Transactions, 2005, , 2876.	3.3	24
124	In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol. European Journal of Pharmacology, 2006, 539, 39-48.	3.5	24
125	Further Studies at Neuropeptide S Position 5: Discovery of Novel Neuropeptide S Receptor Antagonists. Journal of Medicinal Chemistry, 2009, 52, 4068-4071.	6.4	24
126	Dmt-Tic-OH, a highly selective and potent Î´-opioid dipeptide receptor antagonist after systemic administration in the mouse. Life Sciences, 1996, 59, PL93-PL98.	4.3	23

#	Article	IF	Citations
127	Effects of nociceptinNH2 and [Nphe1]nociceptin(1â€“13)NH2 on rat brain noradrenaline release in vivo and in vitro. Neuroscience Letters, 2001, 303, 173-176.	2.1	23
128	Peripheral Mechanisms Involved in Gastric Mucosal Protection by Intracerebroventricular and Intraperitoneal Nociceptin in Rats. Endocrinology, 2005, 146, 3861-3867.	2.8	23
129	The complex-formation behaviour of His residues in the fifth Cu2+ binding site of human prion protein: a close look. New Journal of Chemistry, 2009, 33, 2300.	2.8	23
130	Effect of neuropeptide S receptor antagonists and partial agonists on palatable food consumption in the rat. Peptides, 2011, 32, 44-50.	2.4	23
131	Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt1]N/OFQ(1-13). European Journal of Pharmacology, 2017, 794, 115-126.	3.5	23
132	Helix-Inducing Î±-Aminoisobutyric Acid in Opioid Mimetic Deltorphin C Analogues. Journal of Medicinal Chemistry, 1997, 40, 2579-2587.	6.4	22
133	Supraspinal and spinal effects of [Phe1Î¨(CH2-NH)Gly2]-nociceptin(1â€“13)-NH2 on nociception in the rat. Life Sciences, 1999, 66, 257-264.	4.3	22
134	Assessment of substitution in the second pharmacophore of Dmt-Tic analogues. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2745-2748.	2.2	22
135	Studies of the cardiovascular effects of nociceptin and related peptides. Peptides, 2000, 21, 985-993.	2.4	22
136	The SH3 domain of nebulin binds selectively to type II peptides: theoretical prediction and experimental validation. Journal of Molecular Biology, 2002, 316, 305-315.	4.2	22
137	Nociceptin/Orphanin FQ Modulates Motor Behavior and Primary Motor Cortex Output Through Receptors Located in Substantia Nigra Reticulata. Neuropsychopharmacology, 2009, 34, 341-355.	5.4	22
138	In vitro activity of dermaseptin S1 derivatives against genital pathogens. Apmis, 2010, 118, 674-680.	2.0	22
139	Thermodynamic and spectroscopic investigation on the role of Met residues in CuII binding to the non-octarepeat site of the human prion protein. Metallomics, 2012, 4, 794.	2.4	22
140	Ligands Raise the Constraint That Limits Constitutive Activation in G Protein-coupled Opioid Receptors. Journal of Biological Chemistry, 2013, 288, 23964-23978.	3.4	22
141	Nociceptin/orphanin FQ receptor activation decreases the airway hyperresponsiveness induced by allergen in sensitized mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2013, 304, L657-L664.	2.9	22
142	Optimization of Peptides That Target Human Thymidylate Synthase to Inhibit Ovarian Cancer Cell Growth. Journal of Medicinal Chemistry, 2014, 57, 1355-1367.	6.4	22
143	Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides. Journal of Proteome Research, 2014, 13, 5250-5261.	3.7	22
144	Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity. Journal of Medicinal Chemistry, 2016, 59, 147-156.	6.4	22

#	Article	IF	Citations
145	In vitro pharmacological characterization of a novel unbiased <scp>NOP</scp> receptorâ€selective nonpeptide agonist <scp>AT</scp>â€403. Pharmacology Research and Perspectives, 2017, 5, e00333.	2.4	22
146	Nociceptin/orphanin FQ prevents ethanol-induced gastric lesions in the rat. Regulatory Peptides, 2005, 124, 203-207.	1.9	21
147	Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 148-157.	3.0	21
148	Conformationâ^'Activity Relationship of Neuropeptide S and Some Structural Mutants:Â Helicity Affects Their Interaction with the Receptor. Journal of Medicinal Chemistry, 2007, 50, 4501-4508.	6.4	21
149	Binding of the novel radioligand [3H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 378, 553-561.	3.0	21
150	Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinolineâ€3â€carboxylic acid at position 2. International Journal of Peptide and Protein Research, 1995, 45, 567-573.	0.1	21
151	Synthesis and Separation of the Enantiomers of the Neuropeptide S Receptor Antagonist (9R/S)-3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic Acid 4-Fluoro-benzylamide (SHA 68). Journal of Medicinal Chemistry, 2011, 54, 2738-2744.	6.4	21
152	Intrathecal administration of nociceptin/orphanin FQ receptor agonists in rats: A strategy to relieve chemotherapy-induced neuropathic hypersensitivity. European Journal of Pharmacology, 2015, 766, 155-162.	3.5	21
153	NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine. Psychopharmacology, 2018, 235, 3093-3102.	3.1	21
154	[Nphe1]N/OFQ-(1-13)-NH2 is a competitive and selective antagonist at nociceptin/orphanin FQ receptors mediating K+ channel activation in rat periaqueductal gray slices. Neuropharmacology, 2002, 42, 246-252.	4.1	20
155	Blockade of adenosine A2A receptor counteracts neuropeptide-S-induced hyperlocomotion in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 381, 153-160.	3.0	20
156	Central adenosine A1 and A2A receptors mediate the antinociceptive effects of neuropeptide S in the mouse formalin test. Life Sciences, 2015, 120, 8-12.	4.3	20
157	Synthesis and opioid activity of N,N-Dimethyl-Dmt-Tic-NH-CH(R)-Râ€² analogues: acquisition of potent Î´ antagonism. Bioorganic and Medicinal Chemistry, 2003, 11, 5435-5441.	3.0	19
158	Direct Influence of C-Terminally Substituted Amino Acids in the Dmtâ^'Tic Pharmacophore on Î´-Opioid Receptor Selectivity and Antagonism. Journal of Medicinal Chemistry, 2004, 47, 4066-4071.	6.4	19
159	Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice. Behavioural Brain Research, 2014, 266, 29-36.	2.2	19
160	Medicinal Chemistry, Pharmacology, and Biological Actions of Peptide Ligands Selective for the Nociceptin/Orphanin FQ Receptor. ACS Symposium Series, 2013, , 275-325.	0.5	18
161	Acute and subchronic antinociceptive effects of nociceptin/orphanin FQ receptor agonists infused by intrathecal route in rats. European Journal of Pharmacology, 2015, 754, 73-81.	3.5	18
162	In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations. European Journal of Pharmacology, 2016, 793, 1-13.	3.5	18

#	Article	IF	Citations
163	Mixed Tridentate π -Donor and Monodentate π -Acceptor Ligands as Chelating Systems for Rhenium-188 and Technetium-99m Nitrido Radiopharmaceuticals. Current Radiopharmaceuticals, 2013, 6, 137-145.	0.8	18
164	Urotensin II stimulates plasma extravasation in mice via UT receptor activation. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 370, 347-352.	3.0	17
165	Interaction of calmodulin with the phosphofructokinase target sequence. FEBS Letters, 2004, 577, 284-288.	2.8	17
166	The Interaction of Highly Helical Structural Mutants with the NOP Receptor Discloses the Role of the Address Domain of Nociceptin/Orphanin FQ. Chemistry - A European Journal, 2005, 11, 2061-2070.	3.3	17
167	Nociceptin/orphanin FQ inhibits electrically induced contractions of the human bronchus via NOP receptor activation. Peptides, 2005, 26, 1492-1496.	2.4	17
168	Nociceptin/orphanin FQ prevents gastric damage induced by cold-restraint stress in the rat by acting in the periphery. Peptides, 2007, 28, 1572-1579.	2.4	17
169	Endogenous neuropeptide S tone influences sleepâ€“wake rhythm in rats. Neuroscience Letters, 2014, 581, 94-97.	2.1	17
170	Bioinorganic chemistry of calcitermin â€“ the picklock of its antimicrobial activity. Dalton Transactions, 2019, 48, 13740-13752.	3.3	17
171	Nociceptin Binding Sites in Frog (Rana esculenta) Brain Membranes. Biochemical and Biophysical Research Communications, 1999, 260, 592-596.	2.1	16
172	Effects of [(pF)Phe4]nociceptin/orphanin FQ-(1â€“13)NH2 on GTPÎ³35S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor. European Journal of Pharmacology, 2002, 443, 7-12.	3.5	16
173	Effects of neuropeptide S on seizures and oxidative damage induced by pentylenetetrazole in mice. Pharmacology Biochemistry and Behavior, 2012, 103, 197-203.	2.9	16
174	Neuropeptide S reduces mouse aggressiveness in the resident/intruder test through selective activation of the neuropeptide S receptor. Neuropharmacology, 2015, 97, 1-6.	4.1	16
175	[Nphe1]nociceptin-(1â€“13)NH2 selectively antagonizes nociceptin effects in the rabbit isolated ileum. European Journal of Pharmacology, 2000, 397, 383-388.	3.5	15
176	Conversion of the Potent Î´-Opioid Agonist H-Dmt-Tic-NH-CH2-Bid into Î´-Opioid Antagonists by N-Benzimidazole Alkylation1. Journal of Medicinal Chemistry, 2005, 48, 8112-8114.	6.4	15
177	Structureâ€“activity study at positions 3 and 4 of human neuropeptide S. Bioorganic and Medicinal Chemistry, 2008, 16, 8841-8845.	3.0	15
178	Pharmacological characterization of tachykinin tetrabranched derivatives. British Journal of Pharmacology, 2014, 171, 4125-4137.	5.4	15
179	Urotensin-II peptidomimetic incorporating a non-reducible 1,5-triazole disulfide bond reveals a pseudo-irreversible covalent binding mechanism to the urotensin G-protein coupled receptor. Organic and Biomolecular Chemistry, 2017, 15, 4704-4710.	2.8	15
180	NOP receptor pharmacological profile â€“ A dynamic mass redistribution study. PLoS ONE, 2018, 13, e0203021.	2.5	15

#	Article	IF	Citations
181	Neuropeptide S-initiated sequential cascade mediated by OX1, NK1, mGlu5 and CB1 receptors: a pivotal role in stress-induced analgesia. Journal of Biomedical Science, 2020, 27, 7.	7.0	15
182	Crystal Structures of Dipeptides Containing the Dmt-Tic Pharmacophore. Journal of Medicinal Chemistry, 2002, 45, 5506-5513.	6.4	14
183	Nociceptin/Orphanin FQ(1â€“13)NH2 analogues modified in the Phe1-Gly2 peptide bond. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 365-368.	2.2	14
184	[Nphe1,Arg14,Lys15]N/OFQ-NH2 is a competitive antagonist of NOP receptors in the periaqueductal gray. European Journal of Pharmacology, 2005, 515, 47-53.	3.5	14
185	New approaches to high-throughput structure characterization of SH3 complexes: The example of Myosin-3 and Myosin-5 SH3 domains from S. cerevisiae. Protein Science, 2006, 15, 795-807.	7.6	14
186	Urotensin II evokes neurotransmitter release from rat cerebrocortical slices. Neuroscience Letters, 2008, 440, 275-279.	2.1	14
187	GABAA signalling is involved in N/OFQ anxiolytic-like effects but not in nocistatin anxiogenic-like action as evaluated in the mouse elevated plus maze. Peptides, 2008, 29, 1404-1412.	2.4	14
188	Chronic intracerebroventricular infusion of nociceptin/orphanin FQ increases food and ethanol intake in alcohol-preferring rats. Peptides, 2006, 27, 2803-2810.	2.4	13
189	Role of the ecto-nucleotidases in the cooperative effect of adenosine and neuropeptide-S on locomotor activity in mice. Pharmacology Biochemistry and Behavior, 2011, 99, 726-730.	2.9	13
190	Peptide welding technology â€“ A simple strategy for generating innovative ligands for G protein coupled receptors. Peptides, 2018, 99, 195-204.	2.4	13
191	Folic Acidâ€“Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting. Journal of Medicinal Chemistry, 2021, 64, 3204-3221.	6.4	13
192	High structural side chain specificity required at the second position of immunogenic peptides to obtain stable MHC/peptide complexes. FEBS Letters, 1998, 421, 95-99.	2.8	12
193	Solution structure of nociceptin peptides. Journal of Peptide Science, 2002, 8, 497-509.	1.4	12
194	Proteinase-activated receptor-1 (PAR-1) activation contracts the isolated human renal artery in vitro. British Journal of Pharmacology, 2003, 139, 21-27.	5.4	12
195	The Nociceptin/Orphanin FQ Receptor Antagonist UFP-101 Reduces Microvascular Inflammation to Lipopolysaccharide In Vivo. PLoS ONE, 2013, 8, e74943.	2.5	12
196	Neuropeptide S receptor ligands: a patent review (2005-2016). Expert Opinion on Therapeutic Patents, 2017, 27, 347-362.	5.0	12
197	Zn(II) and Ni(II) complexes with poly-histidyl peptides derived from a snake venom. Inorganica Chimica Acta, 2018, 472, 149-156.	2.4	12
198	Effects of nociceptin and endomorphin 1 on the electrically stimulated human vas deferens. British Journal of Clinical Pharmacology, 2001, 51, 355-358.	2.4	11

#	Article	IF	Citations
199	Inhibition of human multidrug resistance P-glycoprotein 1 by analogues of a potent Î´-opioid antagonist. Brain Research, 2001, 902, 131-134.	2.2	11
200	Intrathecal [Nphe1]nociceptin(1-13)NH2 selectively reduces the spinal inhibitory effect of nociceptin. Life Sciences, 2002, 70, 1151-1157.	4.3	11
201	Disordered Peptides Looking for Their Native Environment: Structural Basis of CB1 Endocannabinoid Receptor Binding to Pepcans. Frontiers in Molecular Biosciences, 2018, 5, 100.	3.5	11
202	Neuropeptide S inhibits stress-stimulated faecal output in the rat. Pharmacological Research, 2011, 64, 471-477.	7.1	10
203	Internalization and Stability of a Thymidylate Synthase Peptide Inhibitor in Ovarian Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 10551-10556.	6.4	10
204	Preferential interaction of the Alzheimer peptide AÎ²â€(1â€“42) with Omegaâ€3â€containing lipid bilayers: structure and interaction studies. FEBS Letters, 2016, 590, 582-591.	2.8	10
205	Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology. Scientific Reports, 2016, 6, 27198.	3.3	10
206	Thermodynamic and spectroscopic study of Cu(<scp>ii</scp>) and Zn(<scp>ii</scp>) complexes with the (148â€“156) peptide fragment of C4YJH2, a putative metal transporter ofCandida albicans. Metallomics, 2019, 11, 1988-1998.	2.4	10
207	Identification of a novel 45ÂkDa protein (JP-45) from rabbit sarcoplasmic-reticulum junctional-face membrane. Biochemical Journal, 2000, 351, 537.	3.7	9
208	Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120. Peptides, 2009, 30, 248-255.	2.4	9
209	Structureâ€“activity relationship study on Tyr9 of urotensin-II(4â€“11): Identification of a partial agonist of the UT receptor. Peptides, 2009, 30, 1130-1136.	2.4	9
210	In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative. Pharmacology Research and Perspectives, 2015, 3, e00108.	2.4	9
211	Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test. Behavioural Brain Research, 2019, 356, 120-126.	2.2	9
212	Synthesis of spinacine and spinacine derivatives: crystal and molecular structures of Nİ€-hydroxymethyl spinacine and NÎ±-methyl spinaceamine. Journal of Chemical Crystallography, 1991, 27, 507-513.	1.1	8
213	Effects of chronic nociceptin/orphanin FQ exposure on cAMP accumulation and receptor density in Chinese hamster ovary cells expressing human nociceptin/orphanin FQ receptors. European Journal of Pharmacology, 2002, 449, 17-22.	3.5	8
214	A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism. Scientific Reports, 2017, 7, 2416.	3.3	8
215	Nociceptin/Orphanin FQ and Urinary Bladder. Handbook of Experimental Pharmacology, 2018, 254, 347-365.	1.8	8
216	Dopamine D1 and D2 receptors mediate neuropeptide S-induced antinociception in the mouse formalin test. European Journal of Pharmacology, 2019, 859, 172557.	3.5	8

#	Article	IF	Citations
217	Cu(II) coordination to His-containing linear peptides and related branched ones: Equalities and diversities. Journal of Inorganic Biochemistry, 2020, 205, 110980.	3.5	8
218	The N-terminal domain of Helicobacter pylori's Hpn protein: The role of multiple histidine residues. Journal of Inorganic Biochemistry, 2021, 214, 111304.	3.5	8
219	Stress induces reinstatement of extinguished cocaine conditioned place preference by a sequential signaling via neuropeptide S, orexin, and endocannabinoid. Addiction Biology, 2021, 26, e12971.	2.6	8
220	Solution structure of nocistatin, a new peptide analgesic. Biopolymers, 2000, 53, 257-264.	2.4	7
221	Functional coupling of the nociceptin/orphanin FQ receptor in dog brain membranes. Brain Research, 2004, 1003, 18-25.	2.2	7
222	Synthesis and pharmacological activity of the Nâ€terminal dermorphin tetrapeptide analogs with CH₂â€NH peptide bond isosteres. International Journal of Peptide and Protein Research, 1992, 40, 437-444.	0.1	7
223	Nociceptin/orphanin FQ induces simultaneously anxiolytic and amnesic effects in the mouse elevated T-maze task. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 33-41.	3.0	7
224	Central noradrenergic activity affects analgesic effect of Neuropeptide S. Journal of Anesthesia, 2018, 32, 48-53.	1.7	7
225	Novel Mixed NOP/Opioid Receptor Peptide Agonists. Journal of Medicinal Chemistry, 2021, 64, 6656-6669.	6.4	7
226	Conformationally constrained amino acids: A concise route to a methionine analogue. Tetrahedron, 1994, 50, 12973-12978.	1.9	6
227	Desensitisation of native and recombinant human urotensin-II receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 380, 451-457.	3.0	6
228	Role of nociceptin/orphanin FQ receptors in the decrease of mucosal mast cells caused by acute stress in the rat colon. Life Sciences, 2011, 89, 735-740.	4.3	6
229	Structure activity studies of nociceptin/orphanin FQ(1â€“13)-NH2 derivatives modified in position 5. Bioorganic and Medicinal Chemistry, 2015, 23, 1515-1520.	3.0	6
230	Structure- and conformation-activity studies of nociceptin/orphanin FQ receptor dimeric ligands. Scientific Reports, 2017, 7, 45817.	3.3	6
231	Pharmacological profile of the neuropeptide S receptor: Dynamic mass redistribution studies. Pharmacology Research and Perspectives, 2018, 6, e00445.	2.4	6
232	Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth. Journal of Medicinal Chemistry, 2018, 61, 7374-7380.	6.4	6
233	Design and Synthesis of 99mTcN-Labeled Dextran-Mannose Derivatives for Sentinel Lymph Node Detection. Pharmaceuticals, 2018, 11, 70.	3.8	6
234	Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1â€“13)-NH₂. Journal of Medicinal Chemistry, 2020, 63, 10782-10795.	6.4	6

#	Article	IF	Citations
235	Pain peptides. Solution structure of orphanin FQ2. FEBS Letters, 2000, 473, 157-160.	2.8	5
236	Study of synthetic peptides derived from the PKI55 protein, a protein kinaseâ€ƒC modulator, in human neutrophils stimulated by the methyl ester derivative of the hydrophobic Nâ€formyl tripeptide forâ€Metâ€Leuâ€Pheâ€OH. FEBS Journal, 2008, 275, 449-457.	4.7	5
237	Quantitative study of [(pF)Phe4,Arg14,Lys15]nociceptin/orphanin FQ-NH2 (UFP-102) at NOP receptors in rat periaqueductal gray slices. European Journal of Pharmacology, 2008, 579, 110-115.	3.5	5
238	Physicochemical stability of cabazitaxel and docetaxel solutions. European Journal of Hospital Pharmacy, 2015, 22, 150-155.	1.1	5
239	DOES hemopressin bind metal ions in vivo?. Dalton Transactions, 2016, 45, 18267-18280.	3.3	5
240	NOP-Targeted Peptide Ligands. Handbook of Experimental Pharmacology, 2018, 254, 17-36.	1.8	5
241	Structureâ€“Activity Relationship Studies on Oxazolo[3,4-a]pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist with Potent In Vivo Activity. Journal of Medicinal Chemistry, 2021, 64, 4089-4108.	6.4	5
242	Characterization of Nociceptin/Orphanin FQ Binding Sites in Dog Brain Membranes. Anesthesia and Analgesia, 2003, 97, 741-747.	2.2	4
243	Nociceptin/Orphanin FQ. , 2013, , 1577-1585.		4
244	Tetrabranched Hetero-Conjugated Peptides as Bifunctional Agonists of the NOP and Mu Opioid Receptors. Bioconjugate Chemistry, 2019, 30, 2444-2451.	3.6	4
245	Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth. Molecules, 2019, 24, 3493.	3.8	4
246	The hypothalamusâ€“pituitaryâ€“adrenal axis does not influence the protective effects of nociceptin/orphanin FQ on the rat gastric mucosa. Regulatory Peptides, 2009, 154, 32-38.	1.9	3
247	Anti-inflammatory and analgesic effects displayed by peptides derived from PKI55 protein, an endogenous protein kinase C inhibitor. Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 382, 193-199.	3.0	3
248	N-Carbamidoyl-4-((3-ethyl-2,4,4-trimethylcyclohexyl)methyl)benzamide Enhances Staurosporine Cytotoxic Effects Likely Inhibiting the Protective Action of Magmas toward Cell Apoptosis. Journal of Medicinal Chemistry, 2014, 57, 4606-4614.	6.4	3
249	Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands. Frontiers in Pharmacology, 2022, 13, 873082.	3.5	3
250	Characterization of N,N(Me)2-Dmt-Tic-OH, a delta selective opioid dipeptide antagonist. NeuroReport, 2000, 11, 2083-2086.	1.2	2
251	Structureâ€“activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11). Peptides, 2008, 29, 674-679.	2.4	2
252	Nociceptin/orphanin FQ and stress regulate synaptophysin expression in the rat fundic and colonic mucosa. Tissue and Cell, 2015, 47, 147-151.	2.2	2

#	Article	IF	Citations
253	Fluorescent opioid receptor ligands as tools to study opioid receptor function. Journal of Pharmacological and Toxicological Methods, 2022, 113, 107132.	0.7	2
254	Use of a Novel Peptide Welding Technology Platform for the Development of B- and T-Cell Epitope-Based Vaccines. Vaccines, 2021, 9, 526.	4.4	1
255	URODYNAMIC AND CLINICAL EVIDENCE OF ACUTE INHIBITORY EFFECTS OF INTRAVESICAL NOCICEPTIN/ORPHANIN FQ ON DETRUSOR OVERACTIVITY IN HUMANS:. Journal of Urology, 2001, , 2237-2240.	0.4	1
256	Ultraselective antagonists of the d-opioid receptor. Expert Opinion on Therapeutic Targets, 1998, 2, 45-47.	1.0	0
257	Computational Chemistry and Opioidmimetics: Receptor-Ligand Interactions of Dmt-Tic Peptides. , 2001, , 851-852.		0
258	Generation of New Dint-Tic Î´ Opioid Antagonists: N-Alkylation. , 2002, , 603-604.		0
259	Synthesis and pharmacological activity of a new antagonist of the OP4 receptor. , 2002, , 227-228.		0